Business Description
CalciMedica is a clinical-stage company working to develop new treatments for serious conditions driven by inflammation, immune system dysfunction, and direct damage to cells. Its primary drug, Auxora, is given intravenously and works by blocking a specific calcium channel in the body, targeting conditions such as acute pancreatitis, kidney injury, and severe COVID-19 pneumonia. The company is also exploring Auxora as a potential therapy for ulcerative colitis, traumatic brain injury, and allergic asthma, while developing oral medications for longer-term inflammatory and immune-related diseases. CalciMedica is headquartered in La Jolla, California.
